Abstract
Pneumocystis jirovecii is an opportunistic pathogen causing life-threatening pneumonia in immunosuppressed patients. The number of non-HIV immunosuppressed patients at risk for Pneumocystis pneumonia is rapidly growing. In contrast to HIV patients, there are no guidelines for Pneumocystis prophylaxis in other immunocompromised hosts. A detailed analysis of current literature data allowed us hereby to define the type of immunocompromised patients for whom evidence suggests a benefit for PCP prophylaxis.
MeSH terms
-
Anti-Infective Agents / administration & dosage*
-
Connective Tissue Diseases / complications
-
Drug-Related Side Effects and Adverse Reactions
-
Evidence-Based Medicine
-
HIV Infections*
-
Humans
-
Immunocompromised Host*
-
Neoplasms / complications
-
Pneumocystis carinii*
-
Pneumonia, Pneumocystis / prevention & control*
-
Practice Guidelines as Topic
-
Protein-Energy Malnutrition / complications
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Transplantation / adverse effects
-
Treatment Outcome
-
Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*
-
Vasculitis / complications
Substances
-
Anti-Infective Agents
-
Trimethoprim, Sulfamethoxazole Drug Combination